Aptevo Therapeutics, Inc. (APVO)

Aptevo Therapeutics' stock has experienced significant volatility. In December 2025, a 1-for-18 reverse stock split was announced. Also in December 2025, shares surged following promising leukemia trial results for mipletamig. In November 2025, Q3 results were reported with an EPS miss and a financial runway into Q4 2026. In April 2024, the stock plummeted after a secondary issue of shares. Overall, the stock has declined substantially over the past year.

Aptevo Therapeutics Inc.'s products are not subject to typical demand seasonality. Demand is primarily driven by clinical trial outcomes, regulatory approvals, physician and patient adoption, disease prevalence, and the competitive landscape.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, utilizing its ADAPTIR® and ADAPTIR-FLEX® platforms. Key product candidates include mipletamig for AML and MDS, ALG.APV-527 for solid tumors, APVO603 for dual co-stimulatory solid tumor targeting, APVO451 and APVO452 as trispecific T-cell engagers, and APVO711 as an immune checkpoint blockade and activator.

Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, and conducts clinical studies across North America and Europe through collaborations.

Aptevo Therapeutics' brand reputation has been influenced by positive clinical developments and stock price declines. Positive Phase 1b trial results for mipletamig boosted reputation and investor sentiment in December 2025. However, the company's stock has significantly declined over the past year, negatively impacting investor confidence. Wall Street analysts currently have a "Hold" consensus rating for APVO shares.

Aptevo Therapeutics Inc. has a mixed ownership structure, with approximately 1.28% held by institutional investors, 1.36% by insiders, and 97.37% by public companies and individual investors. Major institutional owners include Point72 Asset Management, L.P., DRW Securities, LLC, and Virtu Financial LLC. Grant Grady III owns the most shares among individual investors.